Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duo Yu

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Small (Weinheim an Der Bergstrasse, Germany)|December 13, 2024
Isomeric Cu(I) Azolate Frameworks Showing Contrasting Electrocatalytic CO<sub>2</sub> Reduction Selectivities and StabilitiesKai Zheng, Ding-Yi Hu, Chao Wang, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2022
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphomaPengcheng He, Haibo Liu, Bryan Zimdahl, et al.
Angewandte Chemie (International Ed. in English)|May 5, 2022
Flexible Cuprous Triazolate Frameworks as Highly Stable and Efficient Electrocatalysts for CO<sub>2</sub> Reduction with Tunable C<sub>2</sub> H<sub>4</sub> /CH<sub>4</sub> SelectivityLin-Ling Zhuo, Pin Chen, Kai Zheng, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|February 25, 2025
Research progress on the mechanism and treatment of cachexia based on tumor microenvironmentBochen Zhao, Gege Shi, Jiaxin Shi, et al.
Journal of Pharmaceutical Analysis|March 27, 2026
A novel proteolysis-targeting chimera strategy targeting multiple immune checkpoints containing ITIMs enhances antitumor immunityYue-Yuan Qiu, Zhao-Wei Wang, Lei He, et al.
Cell Communication and Signaling : CCS|October 15, 2025
GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinomaGege Shi, Wangqian Zhang, Fei Xie, et al.
Biochemical Pharmacology|January 20, 2026
Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunityMaorong Zhu, Yuxin Wu, Kuo Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 5, 2024
Tumor Microenvironment-Responsive Nanocapsule Delivery CRISPR/Cas9 to Reprogram the Immunosuppressive Microenvironment in Hepatoma CarcinomaLei He, Zhaozhao Li, Danjie Su, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 19, 2026
Uncomplicated Choledocholithiasis in Elderly Patients: A Target Trial Emulation Comparing Observation and ERCP (CHOIcE)Zachary L Smith, Tasmia Amjad, Mikaela Hoard, et al.
Lancet Regional Health. Americas|December 26, 2025
The longitudinal effect of repetition and practice on the accuracy of lay anal examinations for detecting perianal and anal canal abnormalities: a prospective studyAlan G Nyitray, Timothy L McAuliffe, Jenna Nitkowski, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Small (Weinheim an Der Bergstrasse, Germany)|December 13, 2024
Isomeric Cu(I) Azolate Frameworks Showing Contrasting Electrocatalytic CO<sub>2</sub> Reduction Selectivities and StabilitiesKai Zheng, Ding-Yi Hu, Chao Wang, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2022
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphomaPengcheng He, Haibo Liu, Bryan Zimdahl, et al.
Angewandte Chemie (International Ed. in English)|May 5, 2022
Flexible Cuprous Triazolate Frameworks as Highly Stable and Efficient Electrocatalysts for CO<sub>2</sub> Reduction with Tunable C<sub>2</sub> H<sub>4</sub> /CH<sub>4</sub> SelectivityLin-Ling Zhuo, Pin Chen, Kai Zheng, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|February 25, 2025
Research progress on the mechanism and treatment of cachexia based on tumor microenvironmentBochen Zhao, Gege Shi, Jiaxin Shi, et al.
Journal of Pharmaceutical Analysis|March 27, 2026
A novel proteolysis-targeting chimera strategy targeting multiple immune checkpoints containing ITIMs enhances antitumor immunityYue-Yuan Qiu, Zhao-Wei Wang, Lei He, et al.
Cell Communication and Signaling : CCS|October 15, 2025
GFRAL-Fc disarms GDF15 to reprogram tumor immunity and amplify PD-1 efficacy in hepatocellular carcinomaGege Shi, Wangqian Zhang, Fei Xie, et al.
Biochemical Pharmacology|January 20, 2026
Targeted degradation of CD24 by a transferrin receptor-engaging bispecific degrader enhances antitumor immunityMaorong Zhu, Yuxin Wu, Kuo Zhang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 5, 2024
Tumor Microenvironment-Responsive Nanocapsule Delivery CRISPR/Cas9 to Reprogram the Immunosuppressive Microenvironment in Hepatoma CarcinomaLei He, Zhaozhao Li, Danjie Su, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 19, 2026
Uncomplicated Choledocholithiasis in Elderly Patients: A Target Trial Emulation Comparing Observation and ERCP (CHOIcE)Zachary L Smith, Tasmia Amjad, Mikaela Hoard, et al.
Lancet Regional Health. Americas|December 26, 2025
The longitudinal effect of repetition and practice on the accuracy of lay anal examinations for detecting perianal and anal canal abnormalities: a prospective studyAlan G Nyitray, Timothy L McAuliffe, Jenna Nitkowski, et al.
Pageof 9